Liquid Biopsy Goes Beyond Cancer: Diana Abdueva and Maggie Louie, Aqtual

Chapters:

0:00 Liquid biopsy beyond cancer

4:55 Aqtual’s technology

8:55 How would this work in RA?

11:10 Company History

14:55 Test to be launched next year

17:30 Overall Potential

A new precision medicine startup has launched that uses transcriptomic and epigenetic information to help with therapy for a wide range of chronic disorders. Hayward, California-based Aqtual emerged from stealth at the end of last year with data on its first assay, a blood-based test for rheumatoid arthritis.

Today, we’re joined by Diana Abdueva, Aqtual’s Founder and CEO, and Maggie Louie, VP of Translational Research and Strategic Partnerships.

"We are complex organisms that work beautifully for many years,” says Diana in today’s interview.  "But when something goes wrong, it is very hard to detect where the pathology originates.  There are many applications other than oncology, such as dermatology or immunology.”

What are the exciting possibilities for liquid biopsy beyond oncology?